xtlbio.com - XTLB Sales Growth YoY (Last 12 Months)

Geopolitical tensions and sanctions are hindering drug certification, as reflected in the year-over-year rolling commercial revenue trend on the GURU.Markets chart, where this metric stands at 0.00. The brand potential of XTL Biopharmaceuticals (XTLB) is based on patents for the treatment of lupus, while the business relies on venture capital, remaining non-cyclical and independent of GDP phases.
XTL Biopharmaceuticals Ltd. (XTLB) - metric breakdowns and financial figures

The stability of XTL Biopharmaceuticals (XTLB) is determined by the efficiency of external capital raising and its patent portfolio. This indicator measures the percentage change in total revenue over the last 12 months relative to the preceding year. Investors use this tool to monitor business scaling and identify potential overvaluation of the asset. Since the company has not yet reached the commercialization stage, the current 12-month revenue dynamics compared to the same period serve as a marker for the transition to operational activities.